Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine succinate
Drug ID BADD_D00622
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D02570
MeSH ID D000069468
PubChem ID 9800068
TTD Drug ID D0O3FG
NDC Product Code 14778-0606; 53296-0087; 69766-008; 50090-5274; 68788-7488; 51991-312; 68788-7175; 59762-1222; 43063-262; 0008-1222; 51991-311; 59762-1211; 24196-162; 50090-5293; 42816-1210; 0008-1210; 42816-1211; 71335-1150; 68724-1236; 68788-7448; 46708-540; 63629-7559; 14501-0065; 51991-006; 46708-542; 72189-147; 16436-0087; 71205-586; 68180-592; 59762-1210; 0008-1211; 68180-593; 68788-7194; 42816-1222; 46708-541; 65841-173; 50090-4069; 63629-7525
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C20H31NO6
CAS Registry Number 448904-47-0
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anorgasmia19.08.01.001--
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood prolactin increased13.10.03.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Constipation07.02.02.001--
Coronary artery occlusion24.04.04.013; 02.02.01.006--Not Available
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Diarrhoea07.02.01.001--
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Ejaculation delayed21.03.01.001--Not Available
Ejaculation disorder21.03.01.002--
Ejaculation failure21.03.01.003--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling jittery08.01.09.016--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypomania19.16.02.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
The 1th Page    1 2 3    Next   Last    Total 3 Pages